Envista Holdings (NVST) Cash from Financing Activities (2018 - 2026)
Envista Holdings (NVST) posted quarterly Cash from Financing Activities of -$45.6 million for Q2 2026, down 159.09% year-over-year from $77.2 million in Q2 2025, and down 80.95% quarter-over-quarter from -$25.2 million in Q4 2025.
Envista Holdings (NVST) Cash from Financing Activities (2018 - 2026) Analysis & Trends
Envista Holdings' Cash from Financing Activities history runs 9 years deep, the most recent figure standing at -$45.6 million for Q2 2026.
- In Q2 2026, Cash from Financing Activities fell 159.09% year-over-year to -$45.6 million; the TTM figure through Apr 2026 stood at -$198.9 million (down 67.57% YoY), while the FY2025 annual figure was -$170.9 million, down 64.8% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at -$45.6 million, down from -$25.2 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $114.5 million in Q3 2023, with the low at -$100.5 million in Q3 2024.
- The 5-year median for Cash from Financing Activities is -$1.5 million (2023), against an average of -$11.1 million.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities soared 1813.95% in 2022, then plunged 28900.0% in 2025.
- Envista Holdings' Cash from Financing Activities stood at -$68.3 million in 2022, then jumped by 104.83% to $3.3 million in 2023, then sank by 127.27% to -$900000.0 in 2024, then slumped by 2700.0% to -$25.2 million in 2025, then sank by 80.95% to -$45.6 million in 2026.
- Business Quant data shows NVST's Cash from Financing Activities at -$45.6 million in Q2 2026, -$25.2 million in Q4 2025, and -$41.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 134.13 Bn | 128.91 Bn | 1.96 Bn | -287.90 Mn |
| 2 | Becton Dickinson | 52.76 Bn | 51.90 Bn | 2.32 Bn | -577.00 Mn |
| 3 | Alcon | 35.81 Bn | 34.46 Bn | 1.68 Bn | -510.00 Mn |
| 4 | Resmed | 33.72 Bn | 32.25 Bn | 861.22 Mn | -263.16 Mn |
| 5 | Medline | 29.38 Bn | 26.70 Bn | 2.22 Bn | -159.00 Mn |
| 6 | West Pharmaceutical Services | 25.00 Bn | 24.57 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Solventum | 15.46 Bn | 15.06 Bn | 1.29 Bn | -300.00 Mn |
| 8 | Cooper Companies | 14.88 Bn | 14.74 Bn | 735.40 Mn | -75.80 Mn |
| 9 | Baxter International | 13.58 Bn | 11.43 Bn | 1.03 Bn | -31.00 Mn |
| 10 | Envista Holdings | 4.40 Bn | 3.27 Bn | 407.00 Mn | -60.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 3, 2026 | -60.70 Mn |
| Jul 3, 2026 | -60.70 Mn |
| Apr 3, 2026 | -45.60 Mn |
| Apr 3, 2026 | -45.60 Mn |
| Dec 31, 2025 | -25.20 Mn |
| Dec 31, 2025 | -25.20 Mn |
| Sep 26, 2025 | -41.70 Mn |
| Sep 26, 2025 | -41.70 Mn |
| Jun 27, 2025 | -86.40 Mn |
| Jun 27, 2025 | -86.40 Mn |
| Mar 28, 2025 | -17.60 Mn |
| Mar 28, 2025 | -17.60 Mn |
| Dec 31, 2024 | -900,000.00 |
| Dec 31, 2024 | -900,000.00 |
| Sep 27, 2024 | -100.50 Mn |
| Sep 27, 2024 | -100.50 Mn |
| Jun 28, 2024 | 300,000.00 |
| Jun 28, 2024 | 300,000.00 |
| Mar 29, 2024 | -2.60 Mn |
| Mar 29, 2024 | -2.60 Mn |